UK Screening Committee Recommends Limited Prostate Cancer Screening Only for BRCA Carriers
核心洞察
The UK National Screening Committee (搜索) has recommended targeted prostate cancer (搜索) screening only for men with BRCA1 (搜索) or BRCA2 (搜索) gene variants, conducted every two years between ages 45-61.
The recommendation excludes Black men and those with family history but no BRCA mutations, despite these groups having elevated prostate cancer (搜索) risk.
A 23-year European study showed PSA (搜索) screening reduced prostate cancer (搜索) mortality by 13%, preventing 22 deaths per 10,000 men screened.
The UK National Screening Committee (搜索) (NSC) has recommended against widespread prostate cancer (搜索) screening, instead proposing a targeted approach limited to men with confirmed BRCA1 (搜索) or BRCA2 (搜索) gene variants. Under the draft recommendation, only men in this high-risk category would receive screening every two years between ages 45 and 61.
The government will consider the proposal following a 12-week public consultation, with a final decision expected in March. The recommendation has drawn criticism from patient organizations and public figures, including former Prime Minister Rishi Sunak, Olympic cyclist Sir Chris Hoy, and actor Sir Stephen Fry, who have advocated for broader screening programs.
Screening Approach and Current Practice
Currently, men are not automatically offered PSA (搜索) blood tests on the NHS but can request one after age 50, even without symptoms. The PSA test can indicate cancer but also detects benign prostate conditions. Positive results may lead to MRI scans and biopsies, which are generally complication-free but can cause infections, urinary problems, and erectile dysfunction.
Prostate Cancer UK (搜索) criticized the limited recommendation, noting that prostate cancer (搜索) is "the only cancer without a screening programme in the UK" and expressing concern that "thousands of men miss their chance for an early diagnosis."
Evidence Supporting Screening Benefits
Recent data from the long-running European ERSPC study provides compelling evidence for screening benefits. After 23 years of follow-up, published in the New England Journal of Medicine, the study showed that PSA (搜索) screening followed by biopsy reduced mortality by 13% compared to unscreened populations.
The study demonstrated that screening prevented 22 prostate cancer (搜索) deaths per 10,000 men screened, an improvement from 14 deaths per 10,000 at the 16-year follow-up. Additionally, the number of men requiring treatment to prevent one prostate cancer death decreased from 18 to 12 between the two readouts, indicating reduced harm with longer follow-up.
Controversy Over Excluded Groups
The recommendation's exclusion of Black men has generated significant controversy. Black men face approximately twice the risk of developing prostate cancer (搜索) compared to the overall male population, yet they are not included in the proposed screening program. Men with family history of prostate cancer but no BRCA mutations are also excluded.
Sir Chris Hoy, who falls into the family history category and received a terminal prostate cancer (搜索) diagnosis, expressed disappointment with the decision. "While introducing regular checks for men carrying the BRCA genes is a very small step forward, it is not enough," he said, noting that more than 12,000 men in the UK die from prostate cancer annually.
Medical Community Response
Medical organizations including Cancer Research UK and the Royal College of GPs (搜索) have supported the NSC's approach, arguing it balances cancer detection with over-diagnosis risks while avoiding harm from unnecessary interventions for low-risk cancers that would not cause harm.
Dr. Matthew Hobbs, director of research at Prostate Cancer UK (搜索), emphasized the need for evidence on higher-risk groups: "This is exactly the kind of high-quality evidence that the national screening committee needs to consider in its upcoming review – especially for groups who might get more benefit than the 'average man' screened in the ERSPC trial, such as Black men and men with a family history."
Addressing Evidence Gaps
The TRANSFORM clinical trial, launched by Prostate Cancer UK (搜索) with £42 million funding, aims to fill evidence gaps regarding broader screening approaches. The study will test an MRI-refined diagnostic pathway and other screening options, including genetic testing using saliva samples and shorter 'fast MRI' techniques.
TRANSFORM co-lead investigator Rhian Gabe of Queen Mary University of London stated that while screening men with BRCA1 (搜索)/2 variants is commendable, "it now becomes more important than ever to provide evidence to inform policy regarding whole population screening in men and higher risk groups."
Technical Considerations
Oncogenetics specialist Ros Eeles from The Institute of Cancer Research questioned the proposed age cutoff of 61, citing IMPACT screening trial results. "If you stop screening at 61 years of age, you miss nearly half of all cancers for BRCA carriers between 40-69 years," she explained. She also suggested annual screening might be preferable to biennial screening "to avoid the risk that an aggressive cancer could be allowed to grow unchecked for a whole year."
One in 300 people in the population carries a BRCA gene alteration, making the target population for the proposed screening program relatively small. The NSC's final advice will be delivered to health ministers in the four UK nations, who will then decide on their respective screening policies.